Clinicopathological criteria for differential diagnosis of thrombocythemias in various myeloproliferative disorders

Seminars in Thrombosis and Hemostasis

Volumn 32, Issue 3, 2006, Pages 219-230

  Thiele, Juergen ^a   Kvasnicka, Hans Michael ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Bone marrow biopsies; Early polycythemia vera; Histopathology; Initial chronic idiopathic myelofibrosis; Thrombocythemia

Indexed keywords

BLAST CELL CRISIS; BLEEDING; BONE MARROW BIOPSY; CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE COURSE; HISTOPATHOLOGY; HUMAN; MYELOFIBROSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; THROMBOEMBOLISM;

DIAGNOSIS, DIFFERENTIAL; HUMANS; MYELOPROLIFERATIVE DISORDERS; THROMBOCYTHEMIA, HEMORRHAGIC; THROMBOCYTOSIS;

EID: 33646496404     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-939433     Document Type: Review

References (148)

1. Griesshammer M, Bangerter M, Sauer T, Wennauer R, Bergmann L, Heimpel H. Aetiology and clinical significance of thrombocytosis: analysis of 732 patients with an elevated platelet count. J Intern Med 1999;245:295-300
2. Mitus AJ, Schafer AI. Thrombocytosis and thrombocythemia. Hematol Oncol Clin North Am 1990;4:157-178
3. Kutti J. The management of thrombocytosis. Eur J Haematol 1990;44:81-88
4. Santhosh-Kumar CR, Yohannan MD, Higgy KE, al-Mashhadani SA. Thrombocytosis in adults: analysis of 777 patients. J Intern Med 1991;229:493-495
5. Davis WM, Ross AO. Thrombocytosis and thrombocythemia: the laboratory and clinical significance of an elevated platelet count. Am J Clin Pathol 1973;59:243-247
6. Levin J, Conley CL. Thrombocytosis associated with malignant disease. Arch Intern Med 1964;114:497-500
7. Morowitz DA, Allen LW, Kirsner JB. Thrombocytosis in chronic inflammatory bowel disease. Ann Intern Med 1968;68:1013-1021
8. Hirsh J, Dacie JV. Persistent post-splenectomy thrombocytosis and thrombo-embolism: a consequence of continuing anaemia. Br J Haematol 1966;12:44-53
9. Farr M, Scott DL, Constable TJ, Hawker RJ, Hawkins CF, Stuart J. Thrombocytosis of active rheumatoid disease. Ann Rheum Dis 1983;42:545-549
10. Baynes RD, Bothwell TH, Flax H, et al. Reactive thrombocytosis in pulmonary tuberculosis. J Clin Pathol 1987;40:676-679
11. Kutti J, Wadenvik H. Diagnostic and differential criteria of essential thrombocythemia and reactive thrombocytosis. Leuk Lymphoma 1996;22(suppl 1):41-45
12. Schafer AI. Thrombocytosis and thrombocythemia. Blood Rev 2001;15:159-166
13. Schafer AI. Thrombocytosis. N Engl J Med 2004;350:1211-1219
14. Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 2005;128:275-290
15. Bellucci S, Janvier M, Tobelem G, et al. Essential thrombocythemias. Clinical evolutionary and biological data. Cancer 1986;58:2440-2447
16. Van Genderen PJ, Michiels JJ. Primary thrombocythemia: diagnosis, clinical manifestations and management. Ann Hematol 1993;67:57-62
17. Fenaux P, Simon M, Caulier MT, Lai JL, Goudemand J, Bauters F. Clinical course of essential thrombocythemia in 147 cases. Cancer 1990;66:549-556
18. Hehlmann R, Jahn M, Baumann B, Koepcke W. Essential thrombocythemia. Clinical characteristics and course of 61 cases. Cancer 1988;61:2487-2496
19. Chistolini A, Mazzucconi MG, Ferrari A, et al. Essential thrombocythemia: a retrospective study on the clinical course of 100 patients. Haematologica 1990;75:537-540
20. Tefferi A, Silverstein MN, Hoagland HC. Primary thrombocythemia. Semin Oncol 1995;22:334-340
21. Jantunen R, Juvonen E, Ikkala E, et al. Essential thrombocythemia at diagnosis: causes of diagnostic evaluation and presence of positive diagnostic findings. Ann Hematol 1998;77:101-106
22. Besses C, Cervantes F, Pereira A, et al. Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia 1999;13:150-154
23. Colombi M, Radaelli F, Zocchi L, Maiolo AT. Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients. Cancer 1991;67:2926-2930
24. 9/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages. Br J Haematol 1998;100:15-23
25. Regev A, Stark P, Blickstein D, Lahav M. Thrombotic complications in essential thrombocythemia with relatively low platelet counts. Am J Hematol 1997;56:168-172
26. 9/L. Gruppo Italiano Malattie Mieloproliferative Croniche(GIMMC). Haematologica 2000;85:492-495
27. Michiels JJ, Juvonen E. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group. Semin Thromb Hemost 1997;23:339-347
28. Michiels JJ, Thiele J. Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia). Int J Hematol 2002;76:133-145
29. Michiels JJ. Normal life expectancy and thrombosis-free survival in aspirin treated essential thrombocythemia. Clin Appl Thromb Hemost 1999;5:30-36
30. Murphy S, Peterson P, Iland H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 1997;34:29-39
31. Murphy S. Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia. Semin Hematol 1999;36:9-13
32. Pearson TC. Diagnosis and classification of erythrocytoses and thrombocytoses. Baillieres Clin Haematol 1998;11:695-720
33. Tefferi A, Murphy S. Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and management. Blood Rev 2001;15:121-131
34. Finazzi G, Barbui T. Treatment of essential thrombocythemia with special emphasis on leukemogenic risk. Ann Hematol 1999;78:389-392
35. Radaelli F, Mazza R, Curioni E, Ciani A, Pomati M, Maiolo AT. Acute megakaryocytic leukemia in essential thrombocythemia: an unusual evolution? Eur J Haematol 2002;69:108-111
36. Ruggeri M, Finazzi G, Tosetto A, Riva S, Rodeghiero F, Barbui T. No treatment for low-risk thrombocythaemia: results from a prospective study. Br J Haematol 1998;103:772-777
37. Rozman C, Giralt M, Feliu E, Rubio D, Cortes MT. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer 1991;67:2658-2663
38. Barbui T, Finazzi G. Management of essential thrombocythemia. Crit Rev Oncol Hematol 1999;29:257-266
39. Barbui T, Barosi G, Grossi A, et al. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2004;89:215-232
40. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995;332:1132-1136
41. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005;353:33-45
42. Harrison CN, Green AR. Essential thrombocythemia. Hematol Oncol Clin North Am 2003;17:1175-1190
43. Finazzi G, Harrison . Essential thrombocythemia. Semin Hematol 2005;42:230-238
44. Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood 2002;100:4272-4290
45. Sirhan S, Fairbanks VF, Tefferi A. Red cell mass and plasma volume measurements in polycythemia. Cancer 2005;104:213-215
46. Tefferi A. The rise and fall of red cell mass measurement in polycythemia vera. Curr Hematol Rep 2005;4:213-217
47. Pearson TC. Evaluation of diagnostic criteria in polycythemia vera. Semin Hematol 2001;38:21-24
48. Lorberboym M, Rahimi-Levene N, Lipszyc H, Kim CK. Analysis of red cell mass and plasma volume in patients with polycythemia. Arch Pathol Lab Med 2005;129:89-91
49. Fialkow PJ, Faguet GB, Jacobson RJ, Vaidya K, Murphy S. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood 1981;58:916-919
50. Harrison CN, Gale RE, Machin SJ, Linch DC. A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood 1999;93:417-424
51. El-Kassar N, Hetet G, Briere J, Grandchamp B. Clonality analysis of hematopoiesis in essential thrombocythemia: advantages of studying T lymphocytes and platelets. Blood 1997;89:128-134
52. Yan L, Elkassar N, Gardin C, Briere J. Clonality assays and megakaryocyte culture techniques in essential thrombocythemia. Leuk Lymphoma 1996;22(suppl 1):31-40
53. Andreasson B, Lindstedt G, Kutti J. Plasma erythropoietin in essential thrombocythaemia: at diagnosis and in response to myelosuppressive treatment. Leuk Lymphoma 2000;38:113-120
54. Griesshammer M, Kubanek B, Beneke H, et al. Serum erythropoietin and thrombopoietin levels in patients with essential thrombocythaemia. Leuk Lymphoma 2000;36:533-538
55. Griesshammer M, Klippel S, Strunck E, et al. PRV-1 mRNA expression discriminates two types of essential thrombocythemia. Ann Hematol 2004;83:364-370
56. Goerttler PS, Steimle C, Marz E, et al. The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients. Blood 2005;106:2862-2864
57. Westwood NB, Pearson TC. Diagnostic applications of haemopoietic progenitor culture techniques in polycythaemias and thrombocythaemias. Leuk Lymphoma 1996;22(suppl 1):95-103
58. Girodon F, Hermouet S, Dobo I, Mossuz P. Serum erythropoietin values and endogenous erythroid colony growth in erythrocytoses and essential thrombocythaemia. Br J Haematol 2003;120:171 (lett)
59. Eridani S, Sawyer B, Pearson TC. Patterns of in vitro BFU-E proliferation in different forms of polycythaemia and in thrombocythaemia. Eur J Haematol 1987;38:363-369
60. Dobo I, Mossuz P, Campos L, et al. Comparison of four serum-free, cytokine-free media for analysis of endogenous erythroid colony growth in polycythemia vera and essential thrombocythemia. Hematol J 2001;2:396-403
61. Juvonen E, Ikkala E, Oksanen K, Ruutu T. Megakaryocyte and erythroid colony formation in essential thrombocythaemia and reactive thrombocytosis: diagnostic value and correlation to complications. Br J Haematol 1993;83:192-197
62. Florensa L, Besses C, Woessner S, et al. Endogenous megakaryocyte and erythroid colony formation from blood in essential thrombocythaemia. Leukemia 1995;9:271-273
63. Dobo I, Boiret N, Lippert E, et al. A standardized endogenous megakaryocytic erythroid colony assay for the diagnosis of essential thrombocythemia. Haematologica 2004;89:1207-1212
64. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-1148
65. Goldman JM. A unifying mutation in chronic myeloproliferative disorders. N Engl J Med 2005;352:1744-1746
66. Kaushansky K. On the molecular origins of the chronic myeloproliferative disorders: it all makes sense. Blood 2005;105:4187-4190
67. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-1061
68. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-1790
69. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-397
70. Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005;106:2162-2168
71. Zhao R, Xing S, Li Z, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005;280:22788-22792
72. Wolanskyj AP, Lasho TL, Schwager SM, et al. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol 2005;131:208-213
73. Steensma DP, Dewald GW, Lasho TL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and the myelodysplastic syndromes. Blood 2005;106:1207-1209
74. Jelinek J, Oki Y, Gharibyan V, et al. JAK2 mutation 1849G > T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 2005;106:3370-3373
75. Antonioli E, Guglielmelli P, Pancrazzi A, et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 2005;19:1847-1849
76. Tefferi A, Gilliland DG. JAK2 in myeloproliferative disorders is not just another kinase. Cell Cycle 2005;4:1053-1056
77. Gupta R, Abdalla SH, Bain BJ. Thrombocytosis with sideroblastic erythropoiesis: a mixed myeloproliferative myelodysplastic syndrome. Leuk Lymphoma 1999;34:615-619
78. Bain BJ. The relationship between the myelodysplastic syndromes and the myeloproliferative disorders. Leuk Lymphoma 1999;34:443-449
79. Koike T, Uesugi Y, Toba K, et al. 5q-syndrome presenting as essential thrombocythemia: myelodysplastic syndrome or chronic myeloproliferative disorders? Leukemia 1995;9:517-518
80. Mathew P, Tefferi A, Dewald GW, et al. The 5q- syndrome: a single-institution study of 43 consecutive patients. Blood 1993;81:1040-1045
81. Boultwood J, Lewis S, Wainscoat JS. The 5q-syndrome. Blood 1994;84:3253-3260
82. Schmitt-Graeff A, Thiele J, Zuk I, Kvasnicka HM. Essential thrombocythemia with ringed sideroblasts: a heterogeneous spectrum of diseases, but not a distinct entity. Haematologica 2002;87:392-399
83. Stoll DB, Peterson P, Exten R, et al. Clinical presentation and natural history of patients with essential thrombocythemia and the Philadelphia chromosome. Am J Hematol 1988;27:77-83
84. Michiels JJ, Prins ME, Hagermeijer A, et al. Philadelphia chromosome-positive thrombocythemia and megakaryoblast leukemia. Am J Clin Pathol 1987;88:645-652
85. Morris CM, Fitzgerald PH, Hollings PE, et al. Essential thrombocythaemia and the Philadelphia chromosome. Br J Haematol 1988;70:13-19
86. Blickstein D, Aviram A, Luboshitz J, et al. BCR-ABL transcripts in bone marrow aspirates of Philadelphia-negative essential thrombocytopenia patients: clinical presentation. Blood 1997;90:2768-2771
87. Aviram A, Blickstein D, Stark P, et al. Significance of BCR-ABL transcripts in bone marrow aspirates of Philadelphia-negative essential thrombocythemia patients. Leuk Lymphoma 1999;33:77-82
88. Michiels JJ, Berneman ZN, Schroyens W, et al. Philadelphia (Ph) chromosome positive thrombocythemia without features of chronic myeloid leukemia in peripheral blood: natural history and diagnostic differentiation from Ph-negative essential thrombocythemia. Ann Hematol 2004;83:504-512
89. Damaj G, Delabesse E, Le Bihan C, et al. Typical essential thrombocythaemia does not express bcr-abelson fusion transcript. Br J Haematol 2002;116:812-816
90. Thiele J, Kvasnicka HM, Diehl V. Standardization of bone marrow features - does it work in hematopathology for histological discrimination of different disease patterns? Histol Histopathol 2005;20:633-644
91. Girodon F, Bailly F, Barry M, et al. Philadelphia chromosome-positive thrombocythemia without features of chronic myeloid leukemia (CML) in peripheral blood. Ann Hematol 2005;84:409-410
92. Thiele J, Kvasnicka HM, Diehl V, Fischer R, Michiels J. Clinicopathological diagnosis and differential criteria of thrombocythemias in various myeloproliferative disorders by histopathology, histochemistry and immunostaining from bone marrow biopsies. Leuk Lymphoma 1999;33:207-218
93. Georgii A, Buesche G, Kreft A. The histopathology of chronic myeloproliferative diseases. Baillieres Clin Haematol 1998;11:721-749
94. Imbert M, Pierre R, Thiele J, Vardiman JW, Brunning RD, Flandrin G. Essential thrombocythaemia. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. WHO Classification of Tumours: Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:39-41
95. Thiele J, Schneider G, Hoeppner B, Wienhold S, Zankovich R, Fischer R. Histomorphometry of bone marrow biopsies in chronic myeloproliferative disorders with associated thrombocytosis-features of significance for the diagnosis of primary (essential) thrombocythaemia. Virchows Arch A Pathol Anat Histopathol 1988;413:407-417
96. Florena AM, Tripodo C, Iannitto E, Porcasi R, Ingrao S, Franco V. Value of bone marrow biopsy in the diagnosis of essential thrombocythemia. Haematologica 2004;89:911-919
97. Buhr T, Georgii A, Schuppan O, Amor A, Kaloutsi V. Histologic findings in bone marrow biopsies of patients with thrombocythemic cell counts. Ann Hematol 1992;64:286-291
98. Thiele J, Kvasnicka HM, Werden C, Zankovich R, Diehl V, Fischer R. Idiopathic primary osteo-myelofibrosis: a clinicopathological study on 208 patients with special emphasis on evolution of disease features, differentiation from essential thrombocythemia and variables of prognostic impact. Leuk Lymphoma 1996;22:303-317
99. Thiele J, Kvasnicka HM, Boeltken B, Zankovich R, Diehl V, Fischer R. Initial (prefibrotic) stages of idiopathic (primary) myelofibrosis (IMF)-a clinicopathological study. Leukemia 1999;13:1741-1748
100. Thiele J, Kvasnicka HM, Zankovich R, Diehl V. Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis. Haematologica 2000;85:1126-1134
101. Thiele J, Kvasnicka HM. Prefibrotic chronic idiopathic myelofibrosis-a diagnostic enigma? Acta Haematol 2004;111:155-159
102. Thiele J, Kvasnicka HM, Diehl V. Bone marrow features of diagnostic impact in erythrocytosis. Ann Hematol 2005;84:362-367
103. Thiele J, Kvasnicka HM, Orazi A. Bone marrow histopathology in myeloproliferative disorders-current diagnostic approach. Semin Hematol 2005;42:184-195
104. Thiele J, Kvasnicka HM, Zankovich R, Diehl V. The value of bone marrow histology in differentiating between early stage polycythemia vera and secondary (reactive) polycythemias. Haematologica 2001;86:368-374
105. Thiele J, Kvasnicka HM, Diehl V. Initial (latent) polycythemia vera with thrombocytosis mimicking essential thrombocythemia. Acta Haematol 2005;113:213-219
106. Thiele J, Kvasnicka HM. Diagnostic impact of bone marrow histopathology in polycythemia vera (PV). Histol Histopathol 2005;20:317-328
107. Berlin NI. Diagnosis and classification of the polycythemias. Semin Hematol 1975;12:339-351
108. Pierre R, Imbert M, Thiele J, Vardiman JW, RD, Flandrin G. Polycythaemia vera. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. WHO Classification of Tumours: Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:32-38
109. Ruggeri M, Tosetto A, Frezzato M, Rodeghiero F. The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis. Ann Intern Med 2003;139:470-475
110. Pearson TC, Wetherley-Mein G. The course and complications of idiopathic erythrocytosis. Clin Lab Haematol 1979;1:189-196
111. Najean Y, Triebel F, Dresch C. Pure erythrocytosis: reappraisal of a study of 51 cases. Am J Hematol 1981;10:129-136
112. Westwood N, Dudley JM, Sawyer B, Messinezy M, Pearson TC. Primary polycythaemia: diagnosis by non-conventional positive criteria. Eur J Haematol 1993;51:228-232
113. Georgii A, Buhr T, Buesche G, Kreft A, Choritz H. Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies. Leuk Lymphoma 1996;22(suppl 1):15-29
114. Georgii A, Vykoupil KF, Buhr T, et al. Chronic myeloproliferative disorders in bone marrow biopsies. Pathol Res Pract 1990;186:3-27
115. Bartl R, Frisch B, Wilmanns W. Potential of bone marrow biopsy in chronic myeloproliferative disorders (MPD). Eur J Haematol 1993;50:41-52
116. Dickstein JI, Vardiman JW. Issues in the pathology and diagnosis of the chronic myeloproliferative disorders and the myelodysplastic syndromes. Am J Clin Pathol 1993;99:513-525
117. Thiele J, Kvasnicka HM. Diagnostic differentiation of essential thrombocythaemia from thrombocythaemias associated with chronic idiopathic myelofibrosis by discriminate analysis of bone marrow features-a clinicopathological study on 272 patients. Histol Histopathol 2003;18:93-102
118. Thiele J, Kvasnicka HM, Fischer R. Histochemistry and morphometry on bone marrow biopsies in chronic myeloproliferative disorders-aids to diagnosis and classification. Ann Hematol 1999;78:495-506
119. Buhr T, Georgii A, Choritz H. Myelofibrosis in chronic myeloproliferative disorders. Incidence among subtypes according to the Hannover Classification. Pathol Res Pract 1993;189:121-132
120. Vardiman JW. Myelodysplastic syndromes, chronic myeloproliferative diseases, and myelodysplastic/myeloproliferative diseases. Semin Diagn Pathol 2003;20:154-179
121. Thiele J, Imbert M, Pierre R, Vardiman JW, Brunning RD, Flandrin G. Chronic idiopathic myelofibrosis. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. WHO Classification of Tumours: Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:35-38
122. Thiele J, Kvasnicka HM. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients. Ann Hematol 2003;82:148-152
123. Cervantes F, Alvarez-Larran A, Talarn C, Gomez M, Montserrat E. Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients. Br J Haematol 2002;118:786-790
124. Emilia G, Sacchi S, Temperani P, Longo R, Vecchi A. Progression of essential thrombocythemia to blastic crisis via idiopathic myelofibrosis. Leuk Lymphoma 1993;9:423-426
125. Cervantes F, Tassies D, Salgado C, Rovira M, Pereira A, Rozman C. Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients. Acta Haematol 1991;85:124-127
126. Liberato NL, Barosi G, Costa A, D'Elia P, Boccaccio P. Myelofibrosis with myeloid metaplasia following essential thrombocythaemia. Acta Haematol 1989;82:150-153
127. Frei-Lahr D, Barton JC, Hoffman R, Burkett LL, Prchal JT. Blastic transformation of essential thrombocythemia: dual expression of myelomonoblastic/megakaryoblastic phenotypes. Blood 1984;63:866-872
128. Thiele J, Kvasnicka HM, Schmitt-Graeff A, Zankovich R, Diehl V. Follow-up examinations including sequential bone marrow biopsies in essential thrombocythemia (ET): a retrospective clinicopathological study of 120 patients. Am J Hematol 2002;70:283-291
129. Thiele J, Zankovich R, Steinberg T, Kremer B, Fischer R, Diehl V. Primary (essential) thrombocythemia versus initial (hyperplastic) stages of agnogenic myeloid metaplasia with thrombocytosis-a critical evaluation of clinical and histomorphological data. Acta Haematol 1989;81:192-202
130. Thiele J, Kvasnicka HM. Hematopathologic findings in chronic idiopathic myelofibrosis. Semin Oncol 2005;32:380-394
131. Kreft A, Buche G, Ghalibafian M, Buhr T, Fischer T, Kirkpatrick CJ. The incidence of myelofibrosis in essential thrombocythaemia, polycythaemia vera and chronic idiopathic myelofibrosis: a retrospective evaluation of sequential bone marrow biopsies. Acta Haematol 2005;113:137-143
132. Barosi G, Ambrosetti A, Finelli C, et al. The Italian Consensus Conference on diagnostic criteria for myelofibrosis with myeloid metaplasia. Br J Haematol 1999;104:730-737
133. Laszlo J. Myeloproliferative disorders (MPD): myelofibrosis, myelosclerosis, extramedullary hematopoiesis, undifferentiated MPD, and hemorrhagic thrombocythemia. Semin Hematol 1975;12:409-432
134. Barosi G. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol 1999;17:2954-2970
135. Cervantes F, Barosi G, Demory JL, et al. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol 1998;102:684-690
136. Cervantes F, Pereira A, Esteve J, Cobo F, Rozman C, Montserrat E. The changing profile of idiopathic myelofibrosis: a comparison of the presenting features of patients diagnosed in two different decades. Eur J Haematol 1998;60:101-105
137. Cervantes F, Pereira A, Esteve J, et al. Identification of 'short-lived' and 'long-lived' patients at presentation of idiopathic myelofibrosis. Br J Haematol 1997;97:635-640
138. Thiele J, Kvasnicka HM, Zankovich R, Diehl V. Clinical and morphological criteria for the diagnosis of prefibrotic idiopathic (primary) myelofibrosis. Ann Hematol 2001;80:160-165
139. Gatter KC, Cordell JL, Turley H, et al. The immunohistological detection of platelets, megakaryocytes and thrombi in routinely processed specimens. Histopathology 1988;13:257-267
140. Thiele J, Wagner S, Degel C, et al. Megakaryocyte precursors (pro- and megakaryoblasts) in bone marrow tissue from patients with reactive thrombocytosis, polycythemia vera and primary (essential) thrombocythemia. An immunomorphometric study. Virchows Arch B Cell Pathol Ind Mol Pathol 1990;58:295-302
141. Balan KK, Critchley M. Outcome of 259 patients with primary proliferative polycythaemia (PPP) and idiopathic thrombocythaemia (IT) treated in a regional nuclear medicine department with phosphorus-32-a 15 year review. Br J Radiol 1997;70:1169-1173
142. Sterkers Y, Preudhomme C, Lai JL, et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 1998;91:616-622
143. Thiele J, Kvasnicka HM, Zankovich R, Diehl V. Early stage idiopathic (primary) myelofibrosis-current issues of diagnostic features. Leuk Lymphoma 2002;43:1035-1041
144. Thiele J, Kvasnicka HM, Schmitt-Graeff A, Diehl V. Dynamics of fibrosis in chronic idiopathic (primary) myelofibrosis during therapy: a follow-up study on 309 patients. Leuk Lymphoma 2003;44:949-953
145. Buhr T, Buesche G, Choritz H, Langer F, Kreipe H. Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens. Am J Clin Pathol 2003;119:152-158
146. Barosi G, Hoffman R. Idiopathic myelofibrosis. Semin Hematol 2005;42:248-258
147. Annaloro C, Lambertenghi Deliliers G, Oriani A, et al. Prognostic significance of bone marrow biopsy in essential thrombocythemia. Haematologica 1999;84:17-21
148. Kvasnicka HM, Thiele J. The impact of clinicopathological studies in staging and survival in ET, PV and IMF. Semin Thromb Hemost 2006;32: In press